A Study to Evaluate the Effect of Cytochrome P450 (CYP) 3A Inhibitor (Itraconazole) and Inducer (Rifampin) on the Drug Levels of Golcadomide (BMS-986369) in Healthy Participants - Trial NCT06363630
Access comprehensive clinical trial information for NCT06363630 through Pure Global AI's free database. This Phase 1 trial is sponsored by Celgene and is currently Recruiting. The study focuses on Healthy Volunteers. Target enrollment is 36 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Celgene
Timeline & Enrollment
Phase 1
Apr 23, 2024
Aug 19, 2024
Primary Outcome
Maximum observed plasma concentration (Cmax),Area under the plasma concentration-time curve from time zero to time of the last quantifiable concentration (AUC(0-T)),Area under the plasma concentration-time curve from time zero extrapolated to infinite time (AUC(INF))
Summary
The purpose of this study is to evaluate the drug-drug interaction (DDI) potential of
 coadministration of itraconazole or rifampin on the single dose drug levels of golcadomide.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06363630
Non-Device Trial